The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment ...

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys, complying with the ...

World markets are mixed after U.S. stock indexes hit new records. Oil prices fell and U.S. futures were little changed. Japan ...

Sarepta's pause on its prescription gene therapy drug for Duchenne muscular dystrophy gives the company time to work with the FDA on reviews. Infusions nationwide will be canceled. Also in the news, ...